#BEGIN_DRUGCARD DB00043

# AHFS_Codes:
48:92.00

# ATC_Codes:
R03DX05

# Absorption:
Not Available

# Biotransformation:
Most likely removed by opsonization via the reticuloendothelial system.

# Brand_Mixtures:
Not Available

# Brand_Names:
Xolair (Genentech Inc)

# CAS_Registry_Number:
242138-07-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C6450H9916N1714O2023S38

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
>Anti IgE antibody VH domain chain 1
EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNY
ADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVS
SGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSV
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPGK
>Anti IgE antibody VH domain chain 2
EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNY
ADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVS
SGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSV
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPGK
>Anti IgE antibody VL domain chain 1
DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLES
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
>Anti IgE antibody VL domain chain 2
DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLES
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2260565

# Description:
A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin.

# Dosage_Forms:
Powder, for solution	Subcutaneous

# Drug_Category:
Anti-Asthmatic Agents
Immunomodulatory Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
12672069	Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ: Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol. 2003 Apr;33(4):1030-40.

# Drug_Type:
Approved
Biotech
Investigational

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.432

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
J00228

# Generic_Name:
Omalizumab

# HET_ID:
Not Available

# Half_Life:
26 days

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For treatment of asthma caused by allergies

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
43

# Mechanism_Of_Action:
Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils.

# Melting_Point:
61 °C (FAB fragment), 71 °C (whole mAb)

# Molecular_Weight_Avg:
145058.2000

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1IGT

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164752253

# Pharmacology:
Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB00043

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/xolair.htm

# Salts:
Not Available

# Secondary_Accession_No:
BIOD00081
BTD00081

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
liquid

# Structure:
0

# SwissProt_ID:
P01857

# SwissProt_Name:
IGHG1_HUMAN

# Synonyms:
Ig gamma-1 chain C region

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2010-11-13 09:04:02 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Omalizumab

# pKa_Isoelectric_Point:
7.03

# Drug_Target_1_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15356552	Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S: Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004 Sep;114(3):527-30.
17368811	Mirkina I, Schweighoffer T, Kricek F: Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. Immunol Lett. 2007 Apr 15;109(2):120-8. Epub 2007 Mar 1.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
FCER1A

# Drug_Target_1_GenBank_ID_Gene:
X06948

# Drug_Target_1_GenBank_ID_Protein:
31318

# Drug_Target_1_GeneCard_ID:
FCER1A

# Drug_Target_1_Gene_Name:
FCER1A

# Drug_Target_1_Gene_Sequence:
>774 bp
ATGGCTCCTGCCATGGAATCCCCTACTCTACTGTGTGTAGCCTTACTGTTCTTCGCTCCA
GATGGCGTGTTAGCAGTCCCTCAGAAACCTAAGGTCTCCTTGAACCCTCCATGGAATAGA
ATATTTAAAGGAGAGAATGTGACTCTTACATGTAATGGGAACAATTTCTTTGAAGTCAGT
TCCACCAAATGGTTCCACAATGGCAGCCTTTCAGAAGAGACAAATTCAAGTTTGAATATT
GTGAATGCCAAATTTGAAGACAGTGGAGAATACAAATGTCAGCACCAACAAGTTAATGAG
AGTGAACCTGTGTACCTGGAAGTCTTCAGTGACTGGCTGCTCCTTCAGGCCTCTGCTGAG
GTGGTGATGGAGGGCCAGCCCCTCTTCCTCAGGTGCCATGGTTGGAGGAACTGGGATGTG
TACAAGGTGATCTATTATAAGGATGGTGAAGCTCTCAAGTACTGGTATGAGAACCACAAC
ATCTCCATTACAAATGCCACAGTTGAAGACAGTGGAACCTACTACTGTACGGGCAAAGTG
TGGCAGCTGGACTATGAGTCTGAGCCCCTCAACATTACTGTAATAAAAGCTCCGCGTGAG
AAGTACTGGCTACAATTTTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTGGACACA
GGATTATTTATCTCAACTCAGCAGCAGGTCACATTTCTCTTGAAGATTAAGAGAACCAGG
AAAGGCTTCAGACTTCTGAACCCACATCCTAAGCCAAACCCCAAAAACAACTGA

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
1472946	Padlan EA, Helm BA: A modeling study of the alpha-subunit of human high-affinity receptor for immunoglobulin-E. Receptor. 1992 Summer;2(2):129-44.
2964640	Shimizu A, Tepler I, Benfey PN, Berenstein EH, Siraganian RP, Leder P: Human and rat mast cell high-affinity immunoglobulin E receptors: characterization of putative alpha-chain gene products. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1907-11.
2967464	Kochan J, Pettine LF, Hakimi J, Kishi K, Kinet JP: Isolation of the gene coding for the alpha subunit of the human high affinity IgE receptor. Nucleic Acids Res. 1988 Apr 25;16(8):3584.
8125119	Yagi S, Yanagida M, Tanida I, Hasegawa A, Okumura K, Ra C: High-level expression of the truncated alpha chain of human high-affinity receptor for IgE as a soluble form by baculovirus-infected insect cells. Biochemical characterization of the recombinant product. Eur J Biochem. 1994 Mar 1;220(2):593-8.

# Drug_Target_1_HGNC_ID:
HGNC:3609

# Drug_Target_1_HPRD_ID:
00917

# Drug_Target_1_ID:
18

# Drug_Target_1_Locus:
1q23

# Drug_Target_1_Molecular_Weight:
29596

# Drug_Target_1_Name:
High affinity immunoglobulin epsilon receptor subunit alpha

# Drug_Target_1_Number_of_Residues:
257

# Drug_Target_1_PDB_ID:
1RPQ

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00047	ig

# Drug_Target_1_Protein_Sequence:
>High affinity immunoglobulin epsilon receptor alpha-subunit precursor
MAPAMESPTLLCVALLFFAPDGVLAVPQKPKVSLNPPWNRIFKGENVTLTCNGNNFFEVS
STKWFHNGSLSEETNSSLNIVNAKFEDSGEYKCQHQQVNESEPVYLEVFSDWLLLQASAE
VVMEGQPLFLRCHGWRNWDVYKVIYYKDGEALKYWYENHNISITNATVEDSGTYYCTGKV
WQLDYESEPLNITVIKAPREKYWLQFFIPLLVVILFAVDTGLFISTQQQVTFLLKIKRTR
KGFRLLNPHPKPNPKNN

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-25

# Drug_Target_1_Specific_Function:
Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines

# Drug_Target_1_SwissProt_ID:
P12319

# Drug_Target_1_SwissProt_Name:
FCERA_HUMAN

# Drug_Target_1_Synonyms:
Fc-epsilon RI-alpha
FcERI
High affinity immunoglobulin epsilon receptor subunit alpha precursor
IgE Fc receptor, alpha-subunit

# Drug_Target_1_Theoretical_pI:
6.67

# Drug_Target_1_Transmembrane_Regions:
206-224

# Drug_Target_2_Cellular_Location:
Membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17073688	DuBuske LM: IgE, allergic diseases, and omalizumab. Curr Pharm Des. 2006;12(30):3929-44.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
MS4A2

# Drug_Target_2_GenBank_ID_Gene:
D10583

# Drug_Target_2_GenBank_ID_Protein:
219882

# Drug_Target_2_GeneCard_ID:
MS4A2

# Drug_Target_2_Gene_Name:
MS4A2

# Drug_Target_2_Gene_Sequence:
>735 bp
ATGGACACAGAAAGTAATAGGAGAGCAAATCTTGCTCTCCCACAGGAGCCTTCCAGTGTG
CCTGCATTTGAAGTCTTGGAAATATCTCCCCAGGAAGTATCTTCAGGCAGACTATTGAAG
TCGGCCTCATCCCCACCACTGCATACATGGCTGACAGTTTTGAAAAAAGAGCAGGAGTTC
CTGGGGGTAACACAAATTCTGACTGCTATGATATGCCTTTGTTTTGGAACAGTTGTCTGC
TCTGTACTTGATATTTCACACATTGAGGGAGACATTTTTTCATCATTTAAAGCAGGTTAT
CCATTCTGGGGAGCCATATTTTTTTCTATTTCTGGAATGTTGTCAATTATATCTGAAAGG
AGAAATGCAACATATCTGGTGAGAGGAAGCCTGGGAGCAAACACTGCCAGCAGCATAGCT
GGGGGAACGGGAATTACCATCCTGATCATCAACCTGAAGAAGAGCTTGGCCTATATCCAC
ATCCACAGTTGCCAGAAATTTTTTGAGACCAAGTGCTTTATGGCTTCCTTTTCCACTGAA
ATTGTAGTGATGATGCTGTTTCTCACCATTCTGGGACTTGGTAGTGCTGTGTCACTCACA
ATCTGTGGAGCTGGGGAAGAACTCAAAGGAAACAAGGTTCCAGAGGATCGTGTTTATGAA
GAATTAAACATATATTCAGCTACTTACAGTGAGTTGGAAGACCCAGGGGAAATGTCTCCT
CCCATTGATTTATAA

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
1386024	Maekawa K, Imagawa N, Tanaka Y, Harada S: Determination of the sequence coding for the beta subunit of the human high-affinity IgE receptor. FEBS Lett. 1992 May 11;302(2):161-5.
1535625	Kuster H, Zhang L, Brini AT, MacGlashan DW, Kinet JP: The gene and cDNA for the human high affinity immunoglobulin E receptor beta chain and expression of the complete human receptor. J Biol Chem. 1992 Jun 25;267(18):12782-7.
8817330	Hill MR, Cookson WO: A new variant of the beta subunit of the high-affinity receptor for immunoglobulin E (Fc epsilon RI-beta E237G): associations with measures of atopy and bronchial hyper-responsiveness. Hum Mol Genet. 1996 Jul;5(7):959-62.
8842731	Shirakawa T, Mao XQ, Sasaki S, Enomoto T, Kawai M, Morimoto K, Hopkin J: Association between atopic asthma and a coding variant of Fc epsilon RI beta in a Japanese population. Hum Mol Genet. 1996 Aug;5(8):1129-30.
8968765	Shirakawa T, Mao XQ, Sasaki S, Enomoto T, Kawai M, Morimoto K, Hopkin J: Association between atopic asthma and a coding variant of Fc epsilon RI beta in a Japanese population. Hum Mol Genet. 1996 Dec;5(12):2068.

# Drug_Target_2_HGNC_ID:
HGNC:7316

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3862

# Drug_Target_2_Locus:
11q13

# Drug_Target_2_Molecular_Weight:
26534

# Drug_Target_2_Name:
High affinity immunoglobulin epsilon receptor subunit beta

# Drug_Target_2_Number_of_Residues:
244

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF04103	CD20

# Drug_Target_2_Protein_Sequence:
>High affinity immunoglobulin epsilon receptor subunit beta
MDTESNRRANLALPQEPSSVPAFEVLEISPQEVSSGRLLKSASSPPLHTWLTVLKKEQEF
LGVTQILTAMICLCFGTVVCSVLDISHIEGDIFSSFKAGYPFWGAIFFSISGMLSIISER
RNATYLVRGSLGANTASSIAGGTGITILIINLKKSLAYIHIHSCQKFFETKCFMASFSTE
IVVMMLFLTILGLGSAVSLTICGAGEELKGNKVPEDRVYEELNIYSATYSELEDPGEMSP
PIDL

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines

# Drug_Target_2_SwissProt_ID:
Q01362

# Drug_Target_2_SwissProt_Name:
FCERB_HUMAN

# Drug_Target_2_Synonyms:
Fc epsilon receptor I beta-chain
FcERI
IgE Fc receptor subunit beta
Membrane-spanning 4-domains subfamily A member 2

# Drug_Target_2_Theoretical_pI:
4.78

# Drug_Target_2_Transmembrane_Regions:
60-79
98-117
131-150
181-200

#END_DRUGCARD DB00043
